AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for ADP-ribosylation factor-like protein 6

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H0F7

UPID:

ARL6_HUMAN

Alternative names:

Bardet-Biedl syndrome 3 protein

Alternative UPACC:

Q9H0F7; A8KA93; D3DN31

Background:

ADP-ribosylation factor-like protein 6 plays a pivotal role in membrane protein trafficking, particularly at the ciliary organelle base. It is crucial for the BBSome complex recruitment, influencing the sorting of specific membrane proteins to primary cilia. This protein's involvement extends to the regulation of the sonic hedgehog (SHH) pathway and possibly the Wnt signaling cascade, highlighting its significance in cellular signaling and structural integrity.

Therapeutic significance:

Given its association with Bardet-Biedl syndrome 3 and Retinitis pigmentosa 55, understanding the role of ADP-ribosylation factor-like protein 6 could open doors to potential therapeutic strategies. Its critical function in ciliary signaling and assembly suggests that targeting this protein could offer novel approaches for treating these complex genetic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.